Palsonify
What Palsonify is used for
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Palsonify
- Active substance
- paltusotine
- Disease area
- Acromegaly
- Medicine group
- Pituitary and hypothalamic hormones and analogues
- ATC code
- H01CB06
- Marketing authorisation holder
- Crinetics Pharmaceuticals Europe GmbH
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Palsonify
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Palsonify used for?
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
What is the active substance in Palsonify?
Palsonify contains paltusotine.
Who makes Palsonify?
The EU marketing authorisation holder is Crinetics Pharmaceuticals Europe GmbH.
Is Palsonify an orphan medicine?
Yes. Palsonify is designated an orphan medicine in the EU, for a rare disease (Acromegaly).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU